The main result was to look for changes in the cognitive performance of the participants according to different rating scales (e. g., Integrated AD Rating Scale - iADRS, ADAS-Cog13, CDR Sum of Boxes, MMSE, ADCS-iADL), as well as Aβ and tau PET and volumetric MRI. This evidence concerns the gene MAPT and Alzheimer disease.